Israel's Cannabis Research Institutions

Israel's reputation in cannabis is built on more than one famous scientist. A network of universities, research centres and clinical programmes has made the country a genuine world leader in cannabinoid science — and one of the easiest places on earth to actually run a cannabis study. This guide maps that ecosystem.

This guide is informational and is not medical advice.

Why Israel leads

Israel has been conducting clinical research on cannabis longer than any other country, and a key reason is regulatory: the state not only permits cannabis research but funds it, in contrast to countries like the United States where federal restrictions have long impeded clinical study (Merry Jane). That combination — permission, funding and a head start dating to Raphael Mechoulam's work in the 1960s — is the foundation of the country's edge.

The Hebrew University's MCCR

The flagship institution is the Hebrew University of Jerusalem's Multidisciplinary Center for Cannabinoid Research (MCCR), a world leader in the field. Its work is organised across five disciplines — plant research, chemistry, drug development and discovery, pharmacology, and clinical trials — and it studies cannabinoid applications for conditions including cancer, migraines, inflammation, stress, pain and renal disease (AJEM; Canadian Friends of Hebrew University). Researchers such as Yossi Tam at the Hebrew University are among those carrying the work forward.

The Technion and beyond

Cannabis research in Israel is not confined to Jerusalem. The Technion – Israel Institute of Technology hosts prominent cannabinoid work, notably the lab of Dedi Meiri, known for research into cannabis and cancer. Other institutions including Tel Aviv University and the Weizmann Institute of Science — where Mechoulam made his original THC discovery — are part of the research landscape (Times of Israel).

Clinical validation

Beyond basic science, Israeli programmes have pushed into clinical trials across a range of indications — among them Crohn's disease, arthritis, multiple sclerosis, epilepsy and irritable bowel syndrome — and organisations have been set up specifically to give cannabis research clinical validation (Times of Israel). This clinical depth is what turns laboratory findings into evidence that can inform treatment.

Why it matters commercially

This research base is not just academic prestige; it is the country's genuine comparative advantage in cannabis. As our companies coverage notes, Israel struggles to compete on low-cost production — but its science, standards and clinical credibility are real assets, and the reason international players repeatedly turn to Israeli know-how.

For the science itself, see the endocannabinoid system and the entourage effect; for the founding figure, Raphael Mechoulam. More is in our Research hub.